Alexion Pharmaceuticals

Alexion pharmaceuticals is a biotechnology company dedicated to treating patients suffering from rare diseases through the discovery, development and commercialization of medicines. The company develops treatments for conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D). Among its approved medicines are Kanuma, Koselugo, Soliris, Strensiq and Ultomiris, while its pipeline consists of medications focusing on complement biology, hematology, nephrology, neurology, metabolics and cardiology. The company was acquired by AstraZeneca in 2021, following which it was rebranded as Alexion, AstraZeneca Rare Disease.